Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | editorial

Breast cancer—advanced stage: “cure—still a long way to go?”

verfasst von: Herbert Stöger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Excerpt

Metastatic breast cancer (MBC) remains essentially incurable, and goals of therapy include the palliation of symptoms, delay of disease progression, and prolongation of overall survival time without negatively impacting quality of life. Though numerous randomized clinical trials have shown improvements in overall response rates, few have found clear survival benefits. In recent years, however, there has been a small but growing series of clinical trials demonstrating modest, but meaningful survival advantages in metastatic disease [1]. In addition, the development of targeted biologic agents active against MBC, such as trastuzumab, has demonstrated great potential for enhancing the effects of chemotherapy and producing meaningful survival improvements, and thereby presents a new dimension [2]. …
Literatur
1.
Zurück zum Zitat Chia SK, Speers CH, D’yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.CrossRefPubMed Chia SK, Speers CH, D’yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.CrossRefPubMed
2.
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefPubMed Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefPubMed
3.
Zurück zum Zitat Greenberg PA, Hortobagyi GN, Smith TL, et al. Long term follow-up of patients with complete remission following chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.PubMed Greenberg PA, Hortobagyi GN, Smith TL, et al. Long term follow-up of patients with complete remission following chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.PubMed
4.
Zurück zum Zitat Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100:44–52.CrossRefPubMed Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100:44–52.CrossRefPubMed
5.
Zurück zum Zitat Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.CrossRefPubMed Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.CrossRefPubMed
Metadaten
Titel
Breast cancer—advanced stage: “cure—still a long way to go?”
verfasst von
Herbert Stöger, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0022-3

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe